Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical Officer
21 August 2023 - 11:15PM
(NASDAQ: RENB).
Renovaro BioSciences congratulates GEDi Cube on its
appointment of Dr. Lester Russell as Chief Medical Officer. For
more information: (https://gedicube.com/news).
“We are excited about the appointment of Dr.
Russell,” said Dr. Mark Dybul, CEO of Renovaro BioSciences. “As a
seasoned expert in clinical medicine and digital health, he could
enhance the capabilities of GEDi Cube to make a difference in the
lives of people at risk of or suffering from serious
illnesses.”
Renovaro BioSciences announced an exclusive,
binding letter of intent with GEDi Cube on August 9, 2023.
FORWARD-LOOKING STATEMENT
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties,
including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are
forward-looking statements, which can be identified by the use of
forward-looking terminology such as “believes,” “plans,” “expects,”
“aims,” “intends,” “potential,” or similar expressions. All
forward-looking statements are based on assumptions or judgments
about future events and economic conditions that may or may not be
correct or necessarily take place and that are, by their nature,
subject to significant risks, uncertainties, and contingencies.
These forward-looking statements include but are not limited to,
statements regarding the Renovaro-GEDi Cube transaction and
Renovaro’s plans and expectations with respect to the potential
transaction. Actual events or results may differ materially from
those projected in any of such statements due to various
uncertainties, including as set forth in Renovaro BioSciences Inc.
(NASDAQ: RENB) most recent Annual Report on Form 10-K filed with
the SEC, as well as whether: Renovaro and GEDi Cube will enter into
an agreement as to the definitive terms of the transaction; a
condition to consummating the transaction may not be satisfied;
Renovaro may be unable to obtain approval to list on the Nasdaq
Capital Market the shares of Renovaro common stock expected to be
issued pursuant to the transaction; the closing of the transaction
might be delayed or not occur at all. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement, and
Renovaro Biosciences, Inc. undertakes no obligation to revise or
update this shareholder letter to reflect events or circumstances
after the date hereof.
Source: Renovaro Biosciences Inc.
Investor Relations Contact: ir@renovarobio.com
Renovaro (NASDAQ:RENB)
Historical Stock Chart
From Apr 2024 to May 2024
Renovaro (NASDAQ:RENB)
Historical Stock Chart
From May 2023 to May 2024